GEN Exclusives

More »

GEN News Highlights

More »
Jun 22, 2011

Novo Nordisk to Invest $192M in Danish Biopharmaceutical Production Plant

  • Novo Nordisk will invest about DKK 1 billion (roughly €134 million, or $192 million) in the construction of a new facility in Denmark for the production of biopharmaceuticals.

    The new facility, for which the plans have just been approved, will include formulation, freeze-drying, filling, and packaging of a number of Novo Nordisk’s existing and future biopharmaceuticals, including its NovoSeven® hemophilia drug, Norditropin growth hormone and GlucaGen glucagon products.

    The firm says the packaging facility at the new plant is expected to be operational in 2013, with the remaining facilities coming on stream in 2015 after approval. Novo Nordisk already operates a biopharmaceutical production plant in Denmark.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?